Tilray Reports 19% Revenue Growth in Q3, Driven by International Sales Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy TLRY?
Source: stocktwits
- Surge in International Sales: Tilray's Q3 revenue climbed 19% to $206.7 million, driven by a remarkable 73% increase in international sales to $64.8 million, demonstrating strong demand in global markets and solidifying its position in the international cannabis sector.
- Significant Loss Reduction: The company's net loss narrowed dramatically from $793.5 million a year ago to $25.2 million, with loss per share improving to $0.24, although it fell short of the consensus estimate of $0.14, reflecting progress in cost control and operational efficiency.
- EBITDA Outlook Reaffirmed: Tilray reaffirmed its FY2026 EBITDA outlook between $62 million and $72 million, indicating confidence in future profitability, despite a 24% decline in beverage revenue to $42.6 million, with management remaining optimistic about international expansion.
- Investor Sentiment Shift: Following the strong earnings report, Tilray's shares jumped 4% on Wednesday, while retail investor sentiment on Stocktwits shifted from 'neutral' to 'extremely bullish', indicating market recognition of the company's growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 6.860
Low
8.50
Averages
9.57
High
10.00
Current: 6.860
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. It operates through four segments: cannabis operations, beverage operations, distribution operations, and the wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The beverage operations, which encompasses the production, marketing and of beverage products. The distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers. The Wellness products, which encompasses wellness and better-for-you foods and beverages. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, Chowie Wowie and others. It supports over 40 brands in over 20 countries, including cannabis offerings, hemp-based foods and craft beverages.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Reinforces Leadership in Medical Cannabis
- Market Leadership: Tilray holds a leading position in both adult-use and medical markets in Canada, supported by a strong portfolio of brands and deep regulatory expertise, which is expected to drive future growth in the global medical cannabis sector.
- Enhanced Patient Services: Tilray Medical offers over 150 medical cannabis products internationally and has supported more than 400,000 patients, demonstrating its commitment to providing high-quality, reliable medical solutions and further solidifying its market position.
- Science-Driven Innovation: The company focuses on clinical research and physician education to expand access to safe and consistent treatment options, which not only enhances patient treatment experiences but also lays the groundwork for Tilray's continued growth in the global medical market.
- Global Expansion Strategy: Tilray's operations across multiple continents, encompassing pharmaceutical-grade cultivation, production, clinical services, and distribution, ensure the establishment of a patient-centric global platform, reinforcing the company's leadership in the evolving medical cannabis market.
See More
Tilray Brands Faces Significant Challenges in Cannabis Market
- Market Value Collapse: Tilray Brands has seen its stock price plummet by 96% over the past five years, with its market cap dropping from a peak of $20 billion to just $1.5 billion, highlighting the company's struggles in a competitive legal cannabis market.
- Intensified Industry Competition: With approximately 1,000 licensed cannabis companies competing, profit margins are razor-thin, and Tilray faces significant challenges in building brand loyalty due to stringent advertising and packaging restrictions.
- Weak Revenue Growth: Despite a modest 6% increase in net revenue over the past three quarters, Tilray's operating loss remains high at around $47 million, indicating ongoing challenges in achieving profitability.
- Expansion Risks: While Tilray is diversifying into alcohol and international cannabis markets, these ventures are costly and limited in scale, leading to persistent organic growth challenges, compounded by the uncertain timeline for potential U.S. legalization reforms.
See More
Tilray Brands Reports Significant Quarterly Growth
- Revenue Growth: Tilray's net revenue for Q3 fiscal 2026 reached $207 million, an 11% increase year-over-year, and over a four-year period, it has grown by more than 36% compared to $152 million in 2022, demonstrating resilience in a challenging market environment.
- Segment Performance: The beverage segment showed remarkable growth, with sales soaring from $19.6 million to $42.6 million, a 117% increase; however, the core cannabis business only grew by 18%, indicating success in diversifying product lines.
- Market Challenges and Opportunities: Despite significant growth in the beverage sector, the limited prospects for growth in the core cannabis business due to unclear legalization in the U.S. may lead to ongoing market pressures in the future.
- Investment Risk Assessment: Tilray's stock has fallen by 90% over the past four years, reflecting risks associated with weak growth and ongoing losses, making it more suitable for speculators rather than long-term investors, necessitating careful evaluation of its high-risk profile.
See More
Tilray Brands Faces Challenges After BrewDog Acquisition
- Acquisition Update: Tilray acquired UK brewery BrewDog for £33 million ($43.8 million), aiming for a global beverage platform revenue of approximately $500 million annually, although the beer market is currently unfashionable in key regions.
- Stock Price Decline: In March, Tilray's U.S.-listed shares fell nearly 18%, reflecting market concerns over its acquisition and overall business outlook amidst ongoing challenges in both the beer and cannabis industries.
- Analyst Rating Adjustment: TD Cowen's analyst Robert Moskow cut Tilray's price target by 30% to $7 per share while maintaining a buy rating, citing rising aluminum costs as a potential burden on its beer business.
- Industry Struggles: Tilray faces growth challenges in both its cannabis and beer sectors, compounded by high competition and tax rates, leading to investor disappointment regarding its future prospects.
See More
Tilray Launches High-Potency Cannabis Brand PORTAL™
- Brand Launch: Tilray introduces PORTAL™, a brand engineered for high-tolerance consumers, featuring liquid diamonds and precision formulation that ensures each use delivers over 40% THC, addressing the market's demand for high-quality products.
- Product Innovation: The PORTAL lineup includes THCA diamond-coated pre-rolls and liquid diamond vapes, with the former offering bold flavors of watermelon and tropical fruit, while the latter maintains a THC concentration of 95-99%, ensuring powerful effects with every inhale, enhancing user satisfaction.
- Market Positioning: As the cannabis market matures, Tilray fills the gap between consumer expectations and product performance with the PORTAL brand, showcasing its leadership in the premium cannabis sector and further solidifying its market position.
- Sales Channel Expansion: PORTAL products will be available at select retailers across Canada, marking Tilray's strategic expansion in the high-potency cannabis market aimed at attracting high-tolerance users and increasing brand awareness.
See More
Tilray Brands Reports Ongoing Profitability Challenges
- Revenue Growth Stalls: Tilray's net revenue for Q3 Fiscal 2026 rose 11% to $206.7 million, yet the company still reported an operating loss of $26.4 million, indicating persistent challenges in achieving profitability in a highly competitive market.
- Cost Pressures: Despite diversifying into the alcohol sector, Tilray's gross profit was only $55 million, representing 27% of total revenue, while general and administrative expenses exceeded $50.2 million, resulting in a loss before accounting for additional costs.
- Ongoing Expansion Strategy: CEO Irwin D. Simon stated that Tilray is accelerating the development of a scaled global beverage platform, which, while potentially increasing future expenses, shows no signs of slowing down its growth efforts, possibly exacerbating financial pressures.
- Investor Confidence Lacking: Tilray's stock has lost 97% of its value over the past five years; despite business expansion, the lack of profitability leads to cautious investor sentiment, with expectations that the stock price will continue to decline.
See More
Tilray Reinforces Leadership in Medical Cannabis
- Market Leadership: Tilray holds a leading position in both adult-use and medical markets in Canada, supported by a strong portfolio of brands and deep regulatory expertise, which is expected to drive future growth in the global medical cannabis sector.
- Enhanced Patient Services: Tilray Medical offers over 150 medical cannabis products internationally and has supported more than 400,000 patients, demonstrating its commitment to providing high-quality, reliable medical solutions and further solidifying its market position.
- Science-Driven Innovation: The company focuses on clinical research and physician education to expand access to safe and consistent treatment options, which not only enhances patient treatment experiences but also lays the groundwork for Tilray's continued growth in the global medical market.
- Global Expansion Strategy: Tilray's operations across multiple continents, encompassing pharmaceutical-grade cultivation, production, clinical services, and distribution, ensure the establishment of a patient-centric global platform, reinforcing the company's leadership in the evolving medical cannabis market.
See More
Tilray Brands Faces Significant Challenges in Cannabis Market
- Market Value Collapse: Tilray Brands has seen its stock price plummet by 96% over the past five years, with its market cap dropping from a peak of $20 billion to just $1.5 billion, highlighting the company's struggles in a competitive legal cannabis market.
- Intensified Industry Competition: With approximately 1,000 licensed cannabis companies competing, profit margins are razor-thin, and Tilray faces significant challenges in building brand loyalty due to stringent advertising and packaging restrictions.
- Weak Revenue Growth: Despite a modest 6% increase in net revenue over the past three quarters, Tilray's operating loss remains high at around $47 million, indicating ongoing challenges in achieving profitability.
- Expansion Risks: While Tilray is diversifying into alcohol and international cannabis markets, these ventures are costly and limited in scale, leading to persistent organic growth challenges, compounded by the uncertain timeline for potential U.S. legalization reforms.
See More
Tilray Brands Reports Significant Quarterly Growth
- Revenue Growth: Tilray's net revenue for Q3 fiscal 2026 reached $207 million, an 11% increase year-over-year, and over a four-year period, it has grown by more than 36% compared to $152 million in 2022, demonstrating resilience in a challenging market environment.
- Segment Performance: The beverage segment showed remarkable growth, with sales soaring from $19.6 million to $42.6 million, a 117% increase; however, the core cannabis business only grew by 18%, indicating success in diversifying product lines.
- Market Challenges and Opportunities: Despite significant growth in the beverage sector, the limited prospects for growth in the core cannabis business due to unclear legalization in the U.S. may lead to ongoing market pressures in the future.
- Investment Risk Assessment: Tilray's stock has fallen by 90% over the past four years, reflecting risks associated with weak growth and ongoing losses, making it more suitable for speculators rather than long-term investors, necessitating careful evaluation of its high-risk profile.
See More
Tilray Brands Faces Challenges After BrewDog Acquisition
- Acquisition Update: Tilray acquired UK brewery BrewDog for £33 million ($43.8 million), aiming for a global beverage platform revenue of approximately $500 million annually, although the beer market is currently unfashionable in key regions.
- Stock Price Decline: In March, Tilray's U.S.-listed shares fell nearly 18%, reflecting market concerns over its acquisition and overall business outlook amidst ongoing challenges in both the beer and cannabis industries.
- Analyst Rating Adjustment: TD Cowen's analyst Robert Moskow cut Tilray's price target by 30% to $7 per share while maintaining a buy rating, citing rising aluminum costs as a potential burden on its beer business.
- Industry Struggles: Tilray faces growth challenges in both its cannabis and beer sectors, compounded by high competition and tax rates, leading to investor disappointment regarding its future prospects.
See More
Tilray Launches High-Potency Cannabis Brand PORTAL™
- Brand Launch: Tilray introduces PORTAL™, a brand engineered for high-tolerance consumers, featuring liquid diamonds and precision formulation that ensures each use delivers over 40% THC, addressing the market's demand for high-quality products.
- Product Innovation: The PORTAL lineup includes THCA diamond-coated pre-rolls and liquid diamond vapes, with the former offering bold flavors of watermelon and tropical fruit, while the latter maintains a THC concentration of 95-99%, ensuring powerful effects with every inhale, enhancing user satisfaction.
- Market Positioning: As the cannabis market matures, Tilray fills the gap between consumer expectations and product performance with the PORTAL brand, showcasing its leadership in the premium cannabis sector and further solidifying its market position.
- Sales Channel Expansion: PORTAL products will be available at select retailers across Canada, marking Tilray's strategic expansion in the high-potency cannabis market aimed at attracting high-tolerance users and increasing brand awareness.
See More
Tilray Brands Reports Ongoing Profitability Challenges
- Revenue Growth Stalls: Tilray's net revenue for Q3 Fiscal 2026 rose 11% to $206.7 million, yet the company still reported an operating loss of $26.4 million, indicating persistent challenges in achieving profitability in a highly competitive market.
- Cost Pressures: Despite diversifying into the alcohol sector, Tilray's gross profit was only $55 million, representing 27% of total revenue, while general and administrative expenses exceeded $50.2 million, resulting in a loss before accounting for additional costs.
- Ongoing Expansion Strategy: CEO Irwin D. Simon stated that Tilray is accelerating the development of a scaled global beverage platform, which, while potentially increasing future expenses, shows no signs of slowing down its growth efforts, possibly exacerbating financial pressures.
- Investor Confidence Lacking: Tilray's stock has lost 97% of its value over the past five years; despite business expansion, the lack of profitability leads to cautious investor sentiment, with expectations that the stock price will continue to decline.
See More
